PRELUDE THERAPEUTICS INC Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent
PRELUDE THERAPEUTICS INC (PRLD) reported Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent of -$186.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC other comprehensive income (loss), available-for-sale securities adjustment, net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$186.00K.
- PRELUDE THERAPEUTICS INC other comprehensive income (loss), available-for-sale securities adjustment, net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$49.00K.
- PRELUDE THERAPEUTICS INC other comprehensive income (loss), available-for-sale securities adjustment, net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $6.00K.
- PRELUDE THERAPEUTICS INC other comprehensive income (loss), available-for-sale securities adjustment, net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $3.00K, a 99.34% decline year-over-year.
- PRELUDE THERAPEUTICS INC other comprehensive income (loss), available-for-sale securities adjustment, net of tax, portion attributable to parent for fiscal 2025 was -$27.00K.
- PRELUDE THERAPEUTICS INC other comprehensive income (loss), available-for-sale securities adjustment, net of tax, portion attributable to parent for fiscal 2024 was -$188.00K, a 109.82% decline from fiscal 2023.
- PRELUDE THERAPEUTICS INC other comprehensive income (loss), available-for-sale securities adjustment, net of tax, portion attributable to parent for fiscal 2023 was $1.92M.
- PRELUDE THERAPEUTICS INC other comprehensive income (loss), available-for-sale securities adjustment, net of tax, portion attributable to parent for fiscal 2022 was -$981.00K.
| Period end | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$186.00K 10-Q · filed 2026-08-11 | -$235.00K 10-Q · filed 2026-08-11 | -$229.00K derived: sum of 3 quarters · filed 2026-08-11 | -$226.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$49.00K 10-Q · filed 2026-05-12 | -$43.00K derived: sum of 2 quarters · filed 2026-05-12 | -$40.00K derived: sum of 3 quarters · filed 2026-05-12 | -$53.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $9.00K derived: sum of 2 quarters · filed 2026-03-10 | -$4.00K derived: sum of 3 quarters · filed 2026-08-11 | -$27.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | $3.00K 10-Q · filed 2025-11-12 | -$10.00K derived: sum of 2 quarters · filed 2026-08-11 | -$33.00K 10-Q · filed 2025-11-12 | -$165.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$13.00K 10-Q · filed 2026-08-11 | -$36.00K 10-Q · filed 2026-08-11 | -$168.00K derived: sum of 3 quarters · filed 2026-08-11 | $289.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$23.00K 10-Q · filed 2026-05-12 | -$155.00K derived: sum of 2 quarters · filed 2026-05-12 | $302.00K derived: sum of 3 quarters · filed 2026-05-12 | $247.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $325.00K derived: sum of 2 quarters · filed 2026-03-10 | $270.00K derived: sum of 3 quarters · filed 2026-03-10 | -$188.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $457.00K 10-Q · filed 2025-11-12 | $402.00K derived: sum of 2 quarters · filed 2025-11-12 | -$56.00K 10-Q · filed 2025-11-12 | $772.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$55.00K 10-Q · filed 2025-08-14 | -$513.00K 10-Q · filed 2025-08-14 | $315.00K derived: sum of 3 quarters · filed 2025-08-14 | $421.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$458.00K 10-Q · filed 2025-05-06 | $370.00K derived: sum of 2 quarters · filed 2025-05-06 | $476.00K derived: sum of 3 quarters · filed 2025-05-06 | $163.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $828.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $934.00K derived: sum of 2 quarters · filed 2025-03-10 | $621.00K derived: sum of 3 quarters · filed 2025-03-10 | $1.92M 10-K · filed 2025-03-10 |
| 2023-09-30 | $106.00K 10-Q · filed 2024-11-06 | -$207.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.09M 10-Q · filed 2024-11-06 | $1.76M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$313.00K 10-Q · filed 2024-08-12 | $981.00K 10-Q · filed 2024-08-12 | $1.65M derived: sum of 3 quarters · filed 2024-08-12 | $1.58M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $1.29M 10-Q · filed 2024-05-07 | $1.97M derived: sum of 2 quarters · filed 2024-05-07 | $1.90M derived: sum of 3 quarters · filed 2024-05-07 | $1.92M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $671.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $602.00K derived: sum of 2 quarters · filed 2024-02-15 | $621.00K derived: sum of 3 quarters · filed 2024-02-15 | -$981.00K 10-K · filed 2024-02-15 |
| 2022-09-30 | -$69.00K 10-Q · filed 2023-11-01 | -$50.00K derived: sum of 2 quarters · filed 2023-11-01 | -$1.65M 10-Q · filed 2023-11-01 | -$2.19M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $19.00K 10-Q · filed 2023-08-03 | -$1.58M 10-Q · filed 2023-08-03 | -$2.12M derived: sum of 3 quarters · filed 2023-08-03 | -$2.29M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$1.60M 10-Q · filed 2023-05-08 | -$2.14M derived: sum of 2 quarters · filed 2023-05-08 | -$2.31M derived: sum of 3 quarters · filed 2023-05-08 | |
| 2021-12-31 | -$535.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$711.00K derived: sum of 2 quarters · filed 2023-03-15 | -$711.00K 10-K · filed 2023-03-15 | |
| 2021-09-30 | -$176.00K 10-Q · filed 2022-11-14 | -$176.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |